NEW YORK – Prenatal diagnostics firm Sera Prognostics announced Wednesday that it has raised $36 million in Series D financing.
The funding round was led by Blue Ox Healthcare Partners, an investment firm specializing in healthcare companies targeting individuality and value-based care, along with two other unnamed strategic healthcare companies. Existing investors that participated in the round include Domain Associates, InterWest Partners, Laboratory Corporation of America Holdings, Catalyst Health Ventures, and Chione.
The Salt Lake City-based company said the proceeds will be used to increase commercialization of the firm's PreTRM test, a blood biomarker test to determine a woman's risk of premature delivery. The test, which measures and analyzes proteins in the blood predictive of preterm birth, allows for earlier and more proactive clinical decisions to prolong gestation and improve the health of the baby, the company said in a statement.
"We believe PreTRM will be the go-to solution for commercial plans, Medicaid programs, employers, and risk-based providers seeking to effectively manage the clinical and economic epidemic of preterm birth," said Charles Kennedy, managing partner at Blue Ox.